The efficacy of cancer-immunotherapy with complement-activating monoclonal antibodies is
limited by over-expression of one or more membrane-bound complement regulatory …

The overexpression of membrane-bound complement regulatory proteins (mCRP; CD46,
CD55, CD59) preventing opsonization and complement-dependent cytotoxicity (CDC) is …

Overexpression of one or more membrane-bound complement regulatory proteins (mCRPs)
protects tumour cells against complement-mediated clearance by the autologous humoral …

Complement-inhibitory proteins expressed on cancer cells can provide protection from
antitumor antibodies and may potentially modulate the induction of an immune response to …

The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells
to complement-mediated attack, primarily through the over-expression of membrane …

CD59, belonging to membrane complement regulatory proteins (mCRPs), inhibits the
cytolytic activity of complement and is over-expressed in solid cancers, including ovary …

Background Membrane-bound complement restriction proteins (mCRPs) CD46, CD55 and
CD59 enable tumour cells to evade complement dependent cytotoxicity and antibody …

Anti-tumor monoclonal antibody therapy represents one of the earliest targeted therapy in
clinical cancer care and has achieved a great clinical promise. Complement activation …

Complement activation by mAbs can cause direct tumor cell lysis or enhance antibody-
dependent cell-mediated cytotoxicity. However, tumor cells are protected from complement …

Monoclonal antibodies (mAbs) are being increasingly used in cancer therapy owing to their
ability to recognize specifically cancer cells and to activate complement-and cell-mediated …